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Abstract 
Purpose: The most common ocular adverse event following the use of cyclosporine A (CsA) 
0.05% ophthalmic emulsion is ocular burning (17%). Other adverse effects that have been 
reported include conjunctival hyperemia (1–5%), discharge, epiphora, eye pain, foreign body 
sensation, pruritus, stinging and blurred vision. Here, we report a specific side effect of CsA, 
namely eye drop-induced eyelash elongation in a patient with refractory giant papillary 
conjunctivitis.  
Design: Observational case report.  
Methods: Case report and review of the literature.  
Results: A 32-year-old female with giant papillary conjunctivitis on the left eye, who had 
undergone papillectomy 3 years previously and was refractory to topical steroid therapy, 
was treated with CsA 0.05% ophthalmic emulsion (Restasis) 4 times a day, preservative-free 
artificial tears and gentamicin ophthalmic solution in the left eye. After 5 months of topical 
CsA treatment, elongated eyelashes of her left eye were observed without other adverse 
effects.  
Conclusion: Although hypertrichosis and trichomegaly have been documented in the 
literature as side effects of systemic CsA, topical CsA 0.05% eye drop-induced elongated 
eyelashes have not been reported, and we believe ophthalmologists should be mindful and 
inform patients about this specific side effect. 
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Case Report 
A-32-year-old Asian female patient, who had received conjunctival papillectomy on the left eye in 
2002, visited our ophthalmic outpatient department in 2007 complaining of a swollen eyelid and 
discharge from her left eye. The ocular examination revealed notable injected conjunctiva, especially 
over the superior part, and multiple papillae with injected and engorged vessels on the left eye (fig. 
1). 
Due to the suspicion of giant papillary conjunctivitis, she was started on topical steroid 
medications including fluorometholone 0.1% and prednisolone acetate 1% ophthalmic solutions for 2 
months. However, steroid treatment was discontinued due to poor response and an elevated 
intraocular pressure. Therefore, her treatment was switched to topical cyclosporine A (CsA) 0.05% 
ophthalmic emulsion (Restasis) 4 times a day, preservative-free artificial tears and gentamicin 
ophthalmic solution. After 5 months of topical CsA treatment, she came back to our clinic complaining 
of elongated and darkened eyelashes on her left eye without other adverse effects (fig. 2). According 
to the patient, no systemic medications such as calcium channel blockers, erythropoietin or minoxidil 
were used during the treatment period. 
Discussion 
CsA is a hydrophobic, cyclic polypeptide produced as a metabolite by the fungus 
Tolypocladium inflatum. CsA functions as an immunomodulating agent that binds to 
cyclophilin, a cytoplasmic protein, thus interrupting the signaling for interleukin (IL)-2 
production, in addition to inhibiting the proliferation of CD4 T lymphocytes [1]. It also 
has direct inhibitory effects on both eosinophil and mast cell activation [2], which has 
established its role in the treatment of allergic inflammation [2, 3]. In the early 1980s, 
topically applied CsA was first used to inhibit experimental corneal allograft reaction 
[4]. Meanwhile, CsA eye drops were also prescribed for patients with inflammatory 
ocular surface disorders, particularly dry eye syndrome and severe allergic 
keratoconjunctivitis [5]. The current literature supports the safety of topical CsA [6]. 
The major side effect of systemic CsA is nephrotoxicity that is reversible with dosage 
reduction. Other documented adverse reactions to systemic CsA include mild 
hepatotoxicity, hypertension, dose-dependent hypertrichosis and trichomegaly, tremor, 
infection, gum hyperplasia, gastric irritation symptoms and neuropathies [7]. On the 
other hand, adverse events following the use of CsA 0.05% ophthalmic emulsion 
include ocular burning (17%), conjunctival hyperemia (1–5%), discharge, epiphora, eye 
pain, foreign body sensation, pruritus, stinging and blurred vision [6]. However, to our 
knowledge, no CsA ophthalmic emulsion-induced hypertrichosis has been reported in 
the literature to date. The factors that regulate the growth cycle of the eyelash hair 
follicles remain unclear. Paus et al. [8] suggested that CsA induces telogen follicles to 
enter an anagen growth phase, implying a role of CsA in regulating the hair follicle 
immune system and its cellular components through the release of 
inhibitory/stimulatory cytokines [8, 9]. The experiments also indicated that the rate of 
anagen induction is dependent on the dose, time course, and method of administration 
[8]. 
In summary, although rarely encountered, CsA 0.05% ophthalmic emulsion may 
induce the growth of eyelashes, and we believe ophthalmologist should be mindful and 
inform patients treated with topical CsA about this side effect. 
  
Case Rep Ophthalmol 2011;2:398–400 
DOI: 10.1159/000335281 
Published online: 
December 17, 2011 
© 2011 S. Karger AG, Basel 
ISSN 1663–2699 
www.karger.com/cop 
 
 
 
400 
 
Fig. 1. External photographs showing multiple papillae with conjunctival injection (a) and engorged 
vessels (b) over tarsal conjunctiva on the left eye. 
 
 
 
Fig. 2. External photographs demonstrating the normal eyelashes of the right eye (a, arrow) as 
compared to the elongated and darkened eyelashes on the left eye (b, arrow) after 5 months of topical 
CsA treatment. 
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